Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Nagrale, S. Mahakalkar, S. Gaur (Mumbai, Nagpur, India). Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study. Eur Respir J 2013; 42: Suppl. 57, 2833

Member's Comments

No comment yet.

Related content which might interest you: Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022 Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova Source: Eur Respir J, 56 (2) 2000493; 10.1183/13993003.00493-2020 Year: 2020 Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial) Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021 Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010 Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? Source: ERJ Open Res 2016: 00055-2016 Year: 2016 High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021 Year: 2022 Acetylcysteine in treatment of subacute sinusitis, a double blind placebo controlled clinical trial study Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020 Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020 Year: 2020 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Efficacy of a synbiotic supplementation in the prevention of respiratory and intestinal diseases in children: A randomized, double-blind placebo controlled study Source: Annual Congress 2010 - Childhood pneumonia: from prevention to complications Year: 2010 Analysis of the efficacy of moxifloxacin for the treatment of bronchial colonization in COPD patients using microbial molecular typing: a randomized, double-blind, placebo-controlled study Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008 A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001